Group 1 - The company, Lianhuan Pharmaceutical, has received approval from the Food and Drug Administration of Ghana for its tadalafil tablets (20mg) [2] - The registration number for the tadalafil tablets is FDA/GD.255-120251, and the certificate is valid until December 31, 2030 [2]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

江苏联环药业股份有限公司 关于公司获得加纳共和国《药品注册证书》的公告 证券代码：600513 证券简称：联环药业 公告编号：2026-010 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到加纳共和国 （The Republic of Ghana）（全文简称"加纳"）食品药品监督管理局核准签 发的他达拉非片(20mg)（以下简称"该产品"）的《药品注册证书》，现将相 关情况公告如下： 一、《药品注册证书》的基本情况 药品名称：TADALAFIL 20mg TABLETS（他达拉非 20mg 片剂） 剂型：片剂 二、药品的其他相关情况 他达拉非片属于 PDE5 抑制剂药物，是一种磷酸二酯酶抑制剂，适用于治疗 勃起功能障碍合并良性前列腺增生的症状和体征。2024 年度，公司他达拉非片 销售收入为 2,307.93 万元人民币。 截至本公告披露日，公司是唯一一家在加纳持有他达拉非片(20mg)《药品注 册证书》的中国企业（数据来源：加纳共和国食品药品监督管理局官方网站）。 三、对 ...

Core Viewpoint - The company has received regulatory approval for the sale of Tadalafil tablets (20mg) in Ghana, marking a significant step in its international expansion efforts [2] Group 1: Regulatory Approval - The company announced that it has obtained a Drug Registration Certificate from the Food and Drug Authority of the Republic of Ghana for Tadalafil tablets (20mg) [2] - This approval allows the company to legally sell Tadalafil tablets in Ghana, which is a PDE5 inhibitor used for treating erectile dysfunction and benign prostatic hyperplasia symptoms [2] Group 2: Financial Impact - The projected sales revenue for Tadalafil tablets in the fiscal year 2024 is approximately 23.08 million RMB [2] - The company anticipates that the acquisition of the Drug Registration Certificate will not have a significant impact on its recent operating performance [2]

Core Viewpoint - The company has received approval from the Ghana Food and Drug Administration for the registration of Tadalafil tablets (20mg), allowing for legal sales in Ghana [1] Group 1: Product Approval - The approval signifies that Tadalafil tablets (20mg), a PDE5 inhibitor used for treating erectile dysfunction and benign prostatic hyperplasia symptoms, can now be marketed in Ghana [1] - The registration certificate is a crucial step for the company to expand its market presence in West Africa [1] Group 2: Financial Impact - The projected sales revenue for Tadalafil tablets in the fiscal year 2024 is estimated at 23.0793 million RMB [1] - The company anticipates that the approval will not have a significant impact on its recent operating performance [1]

Core Viewpoint - The company has received a drug registration certificate for Tadalafil Tablets (20mg) from the Food and Drugs Authority of Ghana, allowing for legal sales in the country, which supports the company's international market expansion efforts [1] Group 1: Product Approval - The drug Tadalafil (20mg) is classified as a PDE5 inhibitor, used for treating erectile dysfunction and symptoms of benign prostatic hyperplasia [1] - The approval marks a significant step for the company in establishing a presence in the Ghanaian market [1] Group 2: Market Impact - Currently, there is no established sales for Tadalafil in Ghana, and even with potential sales, the revenue contribution is expected to be low relative to the company's overall revenue [1] - The acquisition of the drug registration certificate is not anticipated to have a significant impact on the company's near-term operating performance [1]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical plans to increase the registered capital of its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing), by 50 million RMB to support its strategic development goals [1] - After the capital increase, the registered capital of Lianhuan (Anqing) will rise from 131.52 million RMB to 181.52 million RMB [1] - The funding will be used for key needs such as product research and development, license acquisition, and production line expansion [1]

Core Viewpoint - The company plans to increase the registered capital of its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., by 50 million RMB to support its strategic development and enhance its core competitiveness [1] Group 1: Capital Increase Details - The registered capital of Lianhuan (Anqing) will increase from 131.52 million RMB to 181.52 million RMB following the capital increase [1] - The capital increase will be funded through the company's own and self-raised funds, ensuring no adverse impact on the company's normal operations or cash flow [1] Group 2: Strategic Importance - This capital increase is aligned with the strategic development needs of Lianhuan (Anqing) and will provide a solid foundation for its future production and business development [1] - The company’s current financial status is stable and good, indicating that the capital increase will not harm the interests of the company or its shareholders [1]

Core Viewpoint - The company plans to increase the registered capital of its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., by 50 million RMB to support its strategic development and enhance its core competitiveness [1] Group 1: Capital Increase Details - The registered capital of Lianhuan (Anqing) will increase from 131.52 million RMB to 181.52 million RMB following the capital increase [1] - The capital increase is aimed at meeting key funding needs for product research and development, license acquisition, and production line expansion [1] Group 2: Financial Stability and Impact - The company currently has a stable and good financial condition, and the capital increase will not adversely affect its normal operations or cash flow [1] - The use of self-owned and self-raised funds for the capital increase ensures that there will be no significant negative impact on the company's operating performance or shareholder interests [1]

Group 1 - The company, Lianhuan Pharmaceutical (600513.SH), plans to increase the registered capital of its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., by 50 million RMB, raising it from 131.52 million RMB to 181.52 million RMB [1] - The purpose of this capital increase is to support the strategic development plan of Lianhuan (Anqing) and to meet its funding needs for product research and development, license acquisition, and production line upgrades [1] - This capital increase does not involve related party transactions, does not constitute a major asset restructuring, and does not require approval from the company's shareholders [1] Group 2 - The completion of the capital increase is subject to approval from the relevant state-owned asset authorities, indicating a regulatory requirement [1] - There is uncertainty regarding the operational status and profitability of Lianhuan (Anqing) following the capital increase [1]